GutRecover Therapeutics is a microbiome-focused biotech company developing next-generation solutions to restore intestinal health and address chronic digestive disorders, with a particular focus on post-infectious dysbiosis. U.S.-based and backed by QADR Biotechnology Holding, GutRecover Therapeutics operates a state-of-the-art innovation hub in Morocco to accelerate discovery and globally relevant development.

Our proprietary platform combines advanced microbiome science, multi-omics profiling, strain-specific consortia and biomarker-driven formulations to design targeted interventions that are both clinically rigorous and scalable. By integrating data-driven research with personalized health strategies, we aim to build precision nutraceutical and microbiome-based therapies that complement existing standards of care and fit seamlessly into modern digestive practice.

Our mission is to transform microbiome science into practical, accessible solutions for chronic digestive disorders. We apply state-of-the-art analytical techniques, rigorous testing protocols and real-world evidence to optimize outcomes for patients and healthcare providers. Through our global innovation hub and biotechnology capabilities, GutRecover Therapeutics is building a differentiated pipeline that bridges cutting-edge microbiome research and meaningful patient impact.